Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

3.51USD
26 May 2017
Change (% chg)

$0.14 (+4.15%)
Prev Close
$3.37
Open
$3.36
Day's High
$3.51
Day's Low
$3.36
Volume
1,672
Avg. Vol
4,646
52-wk High
$11.10
52-wk Low
$3.33

GTXI.OQ

Chart for GTXI.OQ

About

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)

Overall

Beta: 1.86
Market Cap(Mil.): $54.06
Shares Outstanding(Mil.): 16.04
Dividend: --
Yield (%): --

Financials

  GTXI.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -1.74 -- --
ROI: -137.75 -8.48 -5.42
ROE: -137.75 -11.31 -4.68

BRIEF-GTX reports Q1 net loss per share of $0.39

* GTX provides corporate update and reports first quarter 2017 financial results

May 15 2017

BRIEF-Gtx Inc qtrly loss per share $0.44

* Gtx provides corporate update and reports fourth quarter and year-end 2016 financial results

Mar 15 2017

BRIEF-Gtx's Enobosarm has been well tolerated among patients

* Enobosarm meets pre-specified primary efficacy endpoint in ongoing phase 2 clinical trial in ER+/AR+ breast cancer

Nov 28 2016

More From Around the Web

Earnings vs. Estimates